Resources

1
17 Oct 2019

Autoantibody levels are associated with acute kidney injury, anemia and post-discharge morbidity and mortality in Ugandan children with severe malaria.

We measured anti-phosphatidylserine (PS) and anti-DNA antibody levels in 382 Ugandan children prospectively recruited in a study of severe malaria (SM)

Sci Rep
Peer-reviewed article
11 Oct 2019

Transcriptional Modulation of the Host Immunity Mediated by Cytokines and Transcriptional Factors in Plasmodium falciparum-Infected Patients of North-East India.

 The transcriptional alterations of major cytokines and immunoregulators were analyzed in this study through gene expression profiling in clinically defined subgroups of P. falciparum patients.

Biomolecules
Peer-reviewed article
09 Oct 2019

Utility of qSOFA and modified SOFA in severe malaria presenting as sepsis.

We conducted a prospective observational study from March 2013 to February 2017 to examine adults admitted with community-acquired infection in a tertiary-care hospital in Ubon Ratchathani, Northeast Thailand (Ubon-sepsis).

PLoS One
Peer-reviewed article
01 Oct 2019

Severe malaria: update on pathophysiology and treatment.

We review recent advances regarding the pathophysiology of severe malaria and treatment recommendations for severe disease in the United States.

Curr Opin Infect Dis
Peer-reviewed article
01 Oct 2019

[Artesunate and severe malaria in paediatrics].

Based on strong studies conducted in Asia and Africa, WHO (World Health Organization) has recommended the use of artesunate as a first-line treatment for severe malaria in adults and children since 2010.

Rev Med Liege
Peer-reviewed article
27 Sep 2019

Antimalarial Medications

Peer-reviewed article
27 Sep 2019

Cerebral Plasmodium falciparum malaria: The role of PfEMP1 in its pathogenesis and immunity, and PfEMP1-based vaccines to prevent it.

We are studying the role of Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) expressed by asexual stages of P. falciparum responsible for the pathogenicity of severe malaria

Immunol Rev
Peer-reviewed article
18 Sep 2019

Plasmodium vivax cerebral malaria in an adult patient in Sudan.

Cases of severe malaria due to P. vivax are emerging in Africa. A few severe P. vivax cases were reported in Eastern Sudan and they were underestimated due to the lack of accurate diagnosis, low parasitaemia

Malar J
Peer-reviewed article
18 Sep 2019

Lung endothelial cell antigen cross-presentation to CD8+T cells drives malaria-associated lung injury.

Here, we confirm that depleting CD8T cells with anti-CD8β antibodies in C57BL/6 mice infected with P. berghei ANKA (PbA) prevent pulmonary vascular leakage. 

Nat Commun
Peer-reviewed article
06 Sep 2019

Exploration of genetic diversity of Plasmodium vivax circumsporozoite protein (Pvcsp) and Plasmodium vivax sexual stage antigen (Pvs25) among North Indian isolates.

The present study was planned to study genetic diversity (Pvcsp and Pvs25) among complicated and uncomplicated P. vivax isolates.

Malar J
Peer-reviewed article
04 Sep 2019

The ferroportin Q248H mutation protects from anemia, but not malaria or bacteremia.

 Using data from cohorts including over 18,000 African children, we show that the Q248H mutation is associated with modest protection against anemia, hemolysis, and iron deficiency, but we found little evidence of protection against severe malaria or bacteremia. 

Sci Adv
Peer-reviewed article
03 Sep 2019

Systematic review of artesunate pharmacokinetics: implication for treatment of resistant malaria.

Artesunate (ART) is an artemisinin derivative used as monotherapy for the treatment of severe malaria and in combination with a partner drug for non-severe malaria.

Int J Infect Dis
Peer-reviewed article

Pages